GT Biopharma, Inc. (GTBP) Financial Statements
Industry: Pharmaceutical Preparations
Net income was -$28.4M, or -$167.00 per diluted share. Operating activities generated -$12.9M of cash, leaving -$12.9M of free cash flow. At fiscal year end, GT Biopharma held $8.1M in total assets against $2.3M in total liabilities, including $6.8M of cash and equivalents.
Open the full interactive GT Biopharma financials → Quarterly statements, key ratios, valuation history and price charts.
GT Biopharma Key Stats
| Share Price | $6.50 |
|---|---|
| Market Cap | $10.1M |
| Dividend Yield | 2.27% |
| 52-Week Range | $0.24 – $11.63 |
| Shares Outstanding | 1.6 million (basic, 2026 Q2) |
GT Biopharma Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | — | — | — | — | — |
| Operating Income | $6.8M | -$57.5M | -$21.3M | -$13.6M | -$14.4M | -$12.4M |
| Pre-Tax Income | -$28.3M | -$58.0M | -$20.9M | -$7.6M | -$13.2M | -$28.4M |
| Net Income | -$28.3M | -$58.0M | -$20.9M | -$7.6M | -$13.2M | -$28.4M |
| Diluted EPS | -$4837.50 | -$1545.00 | — | -$141.00 | -$173.50 | -$167.00 |
GT Biopharma Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Net Income | $8.3M | -$5.7M | -$2.8M | -$4.5M |
| Diluted EPS | $26.00 | -$1.04 | -$2.75 | -$3.00 |
GT Biopharma Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $5.3M | — | $5.7M | $1.1M | $4.0M | $6.8M |
| Current Assets | $5.7M | $32.2M | $16.6M | $14.1M | $4.2M | $8.1M |
| Total Assets | $5.7M | $32.2M | $16.7M | $14.1M | $4.2M | $8.1M |
| Current Liabilities | $35.1M | $10.3M | $4.9M | $6.6M | $5.9M | $2.3M |
| Total Long-Term Debt | $31,000 | — | — | — | — | — |
| Total Liabilities | $35.1M | $10.3M | $5.0M | $6.6M | $5.9M | $2.3M |
| Shareholders' Equity | -$29.4M | $21.9M | $11.7M | $7.5M | -$1.7M | $5.8M |
GT Biopharma Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$7.3M | -$15.6M | -$15.2M | -$8.9M | -$12.9M | -$12.9M |
| Cash From Investing | $0 | -$23.0M | $12.1M | -$2.0M | $12.9M | — |
| Cash From Financing | $12.5M | $42.3M | -$224,000 | $6.3M | $3.0M | $15.8M |
| Free Cash Flow | — | -$15.6M | -$15.2M | -$8.9M | -$12.9M | -$12.9M |
| Dividends Paid | — | — | — | — | — | $229,000 |
Figures from GT Biopharma's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full GT Biopharma financials page for every line item.
GT Biopharma Company Profile
| Ticker | GTBP |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | San Francisco, California |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0000109657 |
Frequently Asked Questions
What was GT Biopharma's net income in fiscal 2025?
GT Biopharma reported net income of -$28.4M for fiscal 2025.
What was GT Biopharma's earnings per share (EPS) in fiscal 2025?
GT Biopharma's diluted EPS was -$167.00 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did GT Biopharma generate in fiscal 2025?
GT Biopharma generated -$12.9M of free cash flow in fiscal 2025.
How many shares of GT Biopharma are outstanding?
GT Biopharma reported a weighted average of 1.6 million basic shares outstanding in 2026 Q2.
What is GT Biopharma's market cap?
Based on its latest closing price, GT Biopharma (GTBP) has a market capitalization of about $10.1M.
When does GT Biopharma's fiscal year end?
GT Biopharma's fiscal year end, as registered with the SEC, is December 31.
Where is GT Biopharma headquartered?
GT Biopharma lists its business address in San Francisco, California in its SEC filings.